Kalaris Therapeutics Board Changes and Executive Compensation
Ticker: KLRS · Form: 8-K · Filed: Nov 3, 2025 · CIK: 1754068
| Field | Detail |
|---|---|
| Company | Kalaris Therapeutics, Inc. (KLRS) |
| Form Type | 8-K |
| Filed Date | Nov 3, 2025 |
| Risk Level | low |
| Pages | 5 |
| Reading Time | 6 min |
| Key Dollar Amounts | $0.0001, $485,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: board-changes, executive-compensation, governance
TL;DR
Kalaris Therapeutics swapped a director, added a new one, and updated exec pay.
AI Summary
Kalaris Therapeutics, Inc. announced on October 28, 2025, the departure of Dr. Michael J. Yaszemski from its Board of Directors. The company also elected Dr. David L. Brown as a new director and appointed him to the Nominating and Governance Committee. Additionally, Kalaris Therapeutics reported on compensatory arrangements for its named executive officers.
Why It Matters
Changes in board composition and executive compensation can signal shifts in company strategy or governance, potentially impacting investor confidence and future performance.
Risk Assessment
Risk Level: low — The filing primarily concerns board appointments and executive compensation, which are routine corporate governance matters.
Key Players & Entities
- Kalaris Therapeutics, Inc. (company) — Registrant
- Dr. Michael J. Yaszemski (person) — Departing Director
- Dr. David L. Brown (person) — Newly Elected Director
- October 28, 2025 (date) — Date of earliest event reported
FAQ
Who has departed from Kalaris Therapeutics' Board of Directors?
Dr. Michael J. Yaszemski has departed from the Board of Directors of Kalaris Therapeutics, Inc.
Who has been elected as a new director to Kalaris Therapeutics' Board?
Dr. David L. Brown has been elected as a new director to Kalaris Therapeutics' Board.
What committee has Dr. David L. Brown been appointed to?
Dr. David L. Brown has been appointed to the Nominating and Governance Committee.
What is the date of the earliest event reported in this 8-K filing?
The date of the earliest event reported in this 8-K filing is October 28, 2025.
What other information is reported in this 8-K filing besides director changes?
The filing also reports on compensatory arrangements of certain officers.
Filing Stats: 1,509 words · 6 min read · ~5 pages · Grade level 12.2 · Accepted 2025-11-03 07:38:37
Key Financial Figures
- $0.0001 — nge on which registered Common Stock, $0.0001 par value per share KLRS The Nasdaq
- $485,000 — ll be paid an annualized base salary of $485,000 and will be eligible to receive an annu
Filing Documents
- d14509d8k.htm (8-K) — 35KB
- d14509dex101.htm (EX-10.1) — 66KB
- 0001193125-25-261697.txt ( ) — 271KB
- klrs-20251028.xsd (EX-101.SCH) — 3KB
- klrs-20251028_def.xml (EX-101.DEF) — 13KB
- klrs-20251028_lab.xml (EX-101.LAB) — 22KB
- klrs-20251028_pre.xml (EX-101.PRE) — 14KB
- d14509d8k_htm.xml (XML) — 5KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits: Exhibit Number Description 10.1 Employment Agreement, dated November 1, 2025, between the Company and Matthew Gall. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. KALARIS THERAPEUTICS, INC. Date: November 3, 2025 By: /s/ Andrew Oxtoby Name: Andrew Oxtoby Title: Chief Executive Officer